Johnson & Johnson (JNJ) reported 4Q earnings on Tue 26 Jan 2016 (before open)

** charts after earnings **

  

Johnson & Johnson beats by $0.02, reports revs in-line; guides FY16 EPS above consensus, revs below consensus  :

• Reports Q4 (Dec) earnings of $1.44 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $1.42; revenues fell 2.4% year/year to $17.81 bln vs the $17.86 bln Capital IQ Consensus. Operational sales results increased 4.4% and the negative impact of currency was 6.8%. Domestic sales increased 8.0%. International sales decreased 11.7%, reflecting operational growth of 1.2% and a negative currency impact of 12.9%. Ex-acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.8%, domestic sales increased 13.4% and international sales increased 2.9%.
  • Worldwide Consumer sales of $13.5 billion for the full-year 2015 represented a decrease of 6.8% versus the prior year, consisting of an operational increase of 2.7% and a negative impact from currency of 9.5%. Domestic sales increased 2.5%; international sales decreased 11.9%, which reflected an operational increase of 2.7% and a negative currency impact of 14.6%.
  • Worldwide Pharma sales of $31.4 billion for the full-year 2015 represented a decrease of 2.7% versus the prior year with an operational increase of 4.2% and a negative impact from currency of 6.9%. Domestic sales increased 5.2%; international sales decreased 12.0%, which reflected an operational increase of 3.0% and a negative currency impact of 15.0%.
  • Worldwide Medical Devices sales of $25.1 billion for the full-year represented a decrease of 8.7% versus the prior year consisting of an operational decrease of 1.4% and a negative currency impact of 7.3%. Domestic sales decreased 1.0%; international sales decreased 14.8%, which reflected an operational decrease of 1.7% and a negative currency impact of 13.1%.
• Co issues guidance for FY16, sees EPS of $6.43-6.58, excluding non-recurring items, vs. $6.40 Capital IQ Consensus; sees FY16 revs +2.3-3.5% (operational) to $70.8-71.5 bln (+4.5-6% adj.) vs. $71.99 bln Capital IQ Consensus.